BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ. The filing adds to a burgeoning IPO queue and caps another busy...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...binding protein A4 S100A7 (psoriasin) - S100 calcium binding protein A7 S100A8 (calgranulin A; MRP8) - S100 calcium binding protein A8...
...for advanced glycation endproducts (RAGE) S100 calcium binding protein A4 (S100A4) Tumor necrosis factor (TNF) S100 calcium binding protein A8 (S100A8) (calgranulin A) (MRP8) S100...
BioCentury | Sep 10, 2019
Distillery Therapeutics

S100A9 could normalize metabolic imbalances from insulin deficiency

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Promoting expression of S100A9, a plasma protein induced by leptin, could treat diabetes. Type I and Type II diabetes induce insulin deficiency, which causes metabolic imbalances including hyperglycemia, hyperglucagonemia, hyperketonemia,...
BioCentury | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in the...
BioCentury | Dec 8, 2017
Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg oral laquinimod (SAIK-MS) missed the primary endpoint of reducing brain atrophy on MRI as measured by percent brain volume change from baseline to week 48 compared to...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Atherosclerosis; hematology Patient sample and mouse studies suggest inhibiting S100A9 could help treat diabetes-related atherosclerosis and thrombocytosis. In plasma samples from Type II diabetes patients, levels of S100A9 were higher than in samples from...
BioCentury | May 12, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS trial

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod (SAIK-MS) missed the primary endpoint in the Phase III CONCERTO trial to treat relapsing-remitting multiple sclerosis (RRMS)....
BioCentury | Mar 29, 2017
Distillery Techniques

Biomarkers

...binding protein (LGALS3BP) , matrix metalloproteinase 9 (MMP9) , S100 calcium binding protein A8 ( S100A8 ; calgranulin A ; MRP8...
...Medical University King's College London Cathepsin D (CTSD) Galectin 3 binding protein (LGALS3BP) Matrix metalloproteinase 9 (MMP9) S100 calcium binding protein A8 (S100A8) (calgranulin A) (MRP8) S100...
BioCentury | Feb 1, 2016
Clinical News

Laquinimod: Phase II amended

Teva amended the double-blind, placebo-controlled, international Phase II LEGATO-HD trial to remove the highest dose -- 1.5 mg/day -- of oral Nerventra laquinimod as recommended by the DSMB. The recommendation followed CV incidents in patients...
BioCentury | Jan 11, 2016
Clinical News

Laquinimod: Phase II amended

Teva and Active said they halted testing of 1.2 and 1.5 mg doses of once-daily oral laquinimod after non-fatal cardiovascular events were observed in the double-blind, placebo-controlled, international Phase II ARPEGGIO and Phase III CONCERTO...
Items per page:
1 - 10 of 132